SM
RIGL icon

SG3 Management’s Rigel Pharmaceuticals RIGL Stock Holding History

SG3 Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5,000
Closed -$150K – 747
2022
Q1 		$150K Buy
+5,000
New +$135K ﹤0.01% 803
2021
Q4 		– Sell
-10,000
Closed -$363K – 1245
2021
Q3 		$363K Buy
10,000
+2,520
+34% +$99.2K 0.01% 667
2021
Q2 		$325K Sell
7,480
-13,850
-65% -$523K 0.01% 731
2021
Q1 		$729K Buy
21,330
+16,180
+314% +$641K 0.02% 682
2020
Q4 		$180K Buy
5,150
+1,400
+37% +$40.5K ﹤0.01% 881
2020
Q3 		$90K Buy
+3,750
New +$92.1K ﹤0.01% 798

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SG3 Management's RIGL Position: Q4 2021 in Review

SG3 Management sold out of Rigel Pharmaceuticals (RIGL) in Q4 2021, closing a stake of 9,196 shares — an estimated $334K sold.

SG3 Management first reported a position in RIGL in Q4 2020 and held it in 4 quarters. The position peaked at $334K in Q3 2021. 162 funds tracked by Wall St. Rank hold RIGL as of Q4 2021.

  • SG3 Management reported no remaining Rigel Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • SG3 Management sold 9,196 Rigel Pharmaceuticals shares in Q4 2021, an estimated $334K.
  • SG3 Management first reported a position in Rigel Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • SG3 Management's Rigel Pharmaceuticals position peaked at $334K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.